Aug
12
Mon
2013
Delegate Talk: BrainSurfer- A Novel Neurofeedback Tool for ADHD Training @ Amriteshwari Hall
Aug 12 @ 3:25 pm – 3:35 pm
Delegate Talk: BrainSurfer- A Novel Neurofeedback Tool for ADHD Training @ Amriteshwari Hall | Vallikavu | Kerala | India

David Ibanez, Laura Dubreuil and Alejandro Rier


Neurofeedback (NF) is a type of biofeedback that uses real time display of electroencephalography to illustrate brain activity. EEG features are extracted and displayed allowing the user to, with practice, modulate their temporal evolution. Neurofeedback training has many therapeutic applications such as attention deficit hyperactivity disorder (ADHD), migraine, depression or conduct disorders. This document presents NeuroSurfer, a novel general-purpose tool for neurofeedback training with a use case of attention deficit hyperactivity disorder (ADHD) treatment.

Aug
13
Tue
2013
Invited Talk: Interrogating Signaling Networks at the Single Cell Level in Primary Human Patient Samples @ Acharya Hall
Aug 13 @ 10:52 am – 11:22 am

MIchelleMichelle Hermiston, MD, Ph.D.
Assistant Professor, Department of Pediatrics University of California San Francisco, USA


Interrogating Signaling Networks at the Single Cell Level In Primary Human Patient Samples

Multiparameter phosphoflow cytometry is a highly sensitive proteomic approach that enables monitoring of biochemical perturbations at the single cell level. By combining antisera to cell surface markers and key intracellular proteins, perturbations in signaling networks, cell survival and apoptosis mediators, cell cycle regulators, and/or modulators of other cellular processes can be analyzed in a highly reproducible and sensitive manner in the basal state and in response to stimulation or drug treatment. Advantages of this approach include the ability to identify the biochemical consequences of genetic and/or epigenetic changes in small numbers of cells, to map potential interplay between various signaling networks simultaneously in a single cell, and to interrogate potential mechanisms of drug resistance or response in a primary patient sample. Application of this technology to patients with acute lymphoblastic leukemia or the autoimmune disease systemic lupus erythematosus (SLE) will be discussed.